REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
ROCKVILLE, Md., Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking place in Porto, Portugal from September 3-6, 2024.
馬里蘭州洛克維爾，2024年8月27日，艾伯維公司（納斯達克股票代碼：RGNX）今天宣佈，將在2024年9月3日至6日於葡萄牙波爾圖舉行的SSIEm 2024年度學術研討會上分享其治療粘多糖沉積症II型（MPS II，也稱爲亨特氏綜合徵）的RGX-121項目數據。
Abstract Title: CAMPSIITE phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II) (PO-205)
Presenter: Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil
Date/Time: Wednesday, September 4, 2024; 6:15 p.m. WEST (Western European Summer Time)
摘要標題：CAMPSIITE I/II/III期：RGX-121的中期臨床更新，這是一項爲治療神經細胞型粘多糖沉積症II型（MPS II）的基因治療試驗（PO-205）。
介紹人：羅伯託·喬利亞尼博士，教授，遺傳學系，UFRGS，匹茲堡聖保羅醫院（HCPA），巴西波爾圖亞雷格里港醫學遺傳學服務。
日期/時間：2024年9月4日（星期三）下午6:15，西歐夏季時間（WESt）。
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
關於regenxbio公司。
REGENXBIO是一家領先的臨床階段生物技術公司，旨在通過基因療法的治癒潛力改善人類生活。自2009年成立以來，REGENXBIO開創了AAV Therapeutics的發展，這是一種創新的基因療法藥物類別。REGENXBIO正在推進一系列用於視網膜和罕見疾病的AAV治療，包括ABBV-RGX-314用於治療激素性黃斑變性和糖尿病性視網膜病變，正在與AbbVie合作開發，RGX-202用於Duchenne的治療和RGX-121用於MPS II的治療。REGENXBIO的AAV Therapeutic平台已經治療了成千上萬的患者，包括諾華的ZOLGENSMA，用於治療脊髓性肌萎縮症的兒童。作爲一次性治療，AAV Therapeutic具有改變數百萬人的健康保健方式的潛力。有關更多信息，請訪問 。
Contacts:
聯繫人：
Dana Cormack
Corporate Communications
[email protected]
達納Cormack
企業通訊
[email protected]
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]
投資者：
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]
SOURCE REGENXBIO Inc.
來源REGENXBIO公司。